Every material Form 8-K Matinas BioPharma Holdings, Inc. has filed with the SEC since September 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Matinas BioPharma Holdings and a former financial advisor terminated their agreement on November 3, 2026. The agreement had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business combinations, and the company paid the advisor $562,500 in cash as part of the termination.
Agreement terminated November 3, 2026 between Matinas and a former financial advisor
Agreement had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business combinations
Company paid the advisor $562,500 in cash; the parties exchanged mutual releases, subject to certain contingencies
Matinas BioPharma's board approved a one-for-fifteen reverse stock split of its common stock, which takes effect at 12:01 a.m. Eastern Time on September 28, 2026, with shares trading on a split-adjusted basis under the symbol MTNB. The filing says each stockholder's ownership percentage and voting power will remain essentially unchanged, and the company states there is no assurance the split will keep its shares listed on the NYSE American.
Reverse split ratio: one-for-fifteen (1:15), approved under authority granted by stockholders on June 23, 2025
Effective date: 12:01 a.m. Eastern Time on September 28, 2026; new CUSIP number 576810 402
Fractional shares will be replaced by a proportional cash payment; holders in brokerage accounts need not act
The company states there can be no assurance the split will enable it to maintain its NYSE American listing
Matinas BioPharma received an NYSE American notice on August 31, 2026, saying it fails the $2.0 million stockholders' equity standard because its equity was $1.8 million as of June 30, 2026. The company already had two other listing deficiencies, and the exchange has granted a plan period through October 2, 2027, after which delisting proceedings may start if it has not regained compliance.
Stockholders' equity was $1.8 million as of June 30, 2026, below the $2.0 million minimum under NYSE American Section 1003(a)(i).
The company is also out of compliance with Sections 1003(a)(ii) ($4.0 million) and 1003(a)(iii) ($6.0 million), as disclosed in earlier filings.
The NYSE American accepted the company's May 4, 2026 plan and set a plan period deadline of October 2, 2027.
Shares continue to trade as MTNB on the NYSE American during the plan period, with a .BC indicator attached.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Matinas BioPharma Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →